4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 53 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,198,751 | -28.0% | 172,722 | +2.2% | 0.00% | -100.0% |
| Q2 2023 | $3,055,348 | +1.3% | 169,084 | -3.7% | 0.00% | 0.0% |
| Q1 2023 | $3,017,120 | -47.9% | 175,516 | -32.7% | 0.00% | 0.0% |
| Q4 2022 | $5,790,235 | +171.0% | 260,704 | -2.0% | 0.00% | – |
| Q3 2022 | $2,137,000 | +149.9% | 265,892 | +117.3% | 0.00% | – |
| Q2 2022 | $855,000 | -53.8% | 122,384 | 0.0% | 0.00% | – |
| Q1 2022 | $1,851,000 | -67.8% | 122,384 | -53.3% | 0.00% | -100.0% |
| Q4 2021 | $5,747,000 | +46.8% | 261,947 | +190.2% | 0.00% | 0.0% |
| Q1 2021 | $3,914,000 | -54.9% | 90,251 | -56.9% | 0.00% | -50.0% |
| Q4 2020 | $8,670,000 | – | 209,179 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |